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Abstract 
This case study follows the development and codification of a Clinical Practice 
Guideline (CPG) by the OB/GYN department of a community hospital. The study 
discusses the history and purpose of CPGs as well as the standards for CPGs in 
different environments. In this case, the CPG was designed to provide evidence-based 
rules for the assessment of a number of “soft” risk factors in deciding whether and when 
to induce labor during the period of 35-38 weeks gestation. The process used to create 
the CPG diverged from the “gold standard” process in several ways, including the use of 
a narrative review of the literature, rather than a systematic review. The case study 
examines whether a systematic review of published research would have led to a 
different CPG. We found that a systematic review did not produce different guidelines 
from those resulting from the narrative review. 
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 Introduction 
Many of the problems in modern medicine can be characterized as problems of 
scale. The complexity and scale at which medicine is practiced are greater now than at 
any time in history: hospitals are larger, the range of diseases that can be treated is 
wider, the number of drugs and tests available is higher, and the mountains of research 
papers are heavier. The variable in this equation that is least able to scale is, 
unfortunately, one that can have a disproportionate influence on medical outcomes – the 
individual physician. 
 The human brain and the human lifespan place inviolable natural limits on all 
physicians. There are limits to how much preparatory education a physician can 
undertake, how many cases a physician can see in a career, and how many courses of 
treatment a physician can memorize. The ongoing division of medical practice into 
smaller and smaller specialties is one attempt to confront the non-scalability of the 
physician, but even this has its limits: by 1996, a general medicine physician would have 
needed to read 7000 journal articles a year merely to remain current on primary 
research in his or her field (and according to self-reported weekly time constraints, the 
physician in question would have needed to budget a mere 30 seconds to reading each 
article)[1]. 
For the last century, the natural limitations on physicians’ time, as well as their 
analytic and mnemonic capacity, have increasingly been seen by public health 
organizations (including governments, hospitals, and trade groups) as obstacles to the 
optimization of the quality of medical practice[2]. However, although the problem has 
long been acknowledged, no consensus solution has ever emerged. The solution that 
has come closest to consensus thus far emerged from a movement known as evidence-
based medicine (EBM), which originated in the 1990s. This title is to some degree a 
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misnomer – medicine has always aspired to be evidence-based, even in antiquity. The 
struggle, rather, has been over the definition of “evidence.” If one thinks of evidence in 
the sense of “crime scene evidence,” the modern medical patient is a limitless fountain 
of evidence. Detailed medical histories can be taken, hundreds of tests can yield 
thousands of numerical results, and entire genomes can even be sequenced. Physicians 
are awash in such “evidence” generated at each encounter. However, advocates of EBM 
see this as more of a handicap than an advantage: despite years of training and 
experience, physicians still have difficulty reliably distinguishing evidence that is relevant 
to care-related decisions from evidence that is irrelevant or misleading. For them, it is as 
if a detective investigating a homicide were unsure whether the channel playing on the 
victim’s television meant that the murderer used a gun or a knife. 
In fact, the E in EBM is more properly understood as effectiveness. To establish 
the efficacy of any given treatment, it is necessary first to scientifically establish that the 
treatment is correlated with a desirable outcome, and then to eliminate any spurious or 
confounding correlations, i.e. any other common element that might have a causal 
connection to the desired outcome. If the treatment continues to be associated with the 
desired outcome when deployed in real-world circumstances, this demonstrates its 
effectiveness. Advocates of EBM sought to identify which treatments were most likely to 
result in good outcomes, how often, and under what conditions. To achieve this goal, 
they closely analyzed the conditions under which research was being conducted and 
issued guidance to “teach doctors to examine the medical literature critically” [2] – in 
other words, to help medical professionals understand how much confidence one should 
have that the results of a given study could be generalized. Unfortunately, advocates of 
EBM found that, as Weisz et al. put it, “most doctors would not or could not directly 
evaluate the literature themselves[2].” To resolve this problem, advocates of EBM – 
which by the late 1990s had redefined itself as the more pragmatic “evidence-based 
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practice” (EBP) – co-opted an existing concept, the medical guideline, retitling it the 
Clinical Practice Guideline (CPG). 
 A medical guideline is a document that attempts to distill a large corpus of 
expertise, experience, and/or evidence down to essential rules. It directs physicians to 
provide certain treatments and interventions under certain conditions; its most basic 
formulation is “if X, then Y.” The concept of a medical guideline had been in use since 
the early 20th century, when the growth of hospitals and third-party payers such as 
governments led to the first published guidelines for care. For example, the standards 
published in 1916 by the Associated Out-Patient Clinics of the City of New York set 
guidelines in subjects as varied as “space requirements, personnel, the kind of patients 
to be treated, record keeping and history taking”[3]. In the UK, the government-backed 
Radium Commission forced hospitals purchasing radium to adopt “specific standards of 
therapeutic practice”[2] as early as 1929. In 1955, the National Tuberculosis Association 
and the American Academy of Pediatrics both issued guidelines specifically addressing 
diagnosis and treatment. By this time, the demand for medical guidelines was well 
established: a search of national library catalogs in the US, UK, and France by Weisz et 
al. found over fifty medical guidelines published in the thirty years following World War II 
alone[2]. 
Guidelines were seen as documents reflecting “consensus,” i.e. the majority 
opinion of expert practitioners in that field – said experts being selected, again, by 
consensus. The late 1970s saw the rise of guidelines produced in “consensus 
conferences,” in which “the authority of experts in different fields was supplemented by 
both consumer representatives and strict procedural protocols[2].” Such guidelines 
ensured that an institution that followed them would be practicing medicine of the same 
quality as other institutions, but not that the institution would be practicing medicine that 
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achieved optimal outcomes. No systems were in place to ensure that the experts in 
these conferences were basing their opinions on anything stronger than anecdote. 
The term clinical practice guideline begins to appear in the literature around 
1991, reflecting the rise of EBM/EBP. Advocates of EBP sought to define a clinical 
practice guideline as a medical guideline based less on existing consensus and more on 
systematic reviews of research literature that give greater weight to results obtained 
under optimal evidentiary conditions, such as double-blinded randomized clinical trials. A 
side effect of this has been to advance the proliferation of guidelines – an institution 
wishing to produce or update a clinical practice guideline no longer needs to host a 
conference of eminent practitioners; one might facetiously claim that it simply needs to 
lock a team of information scientists in a room with a rubric and a connection to PubMed. 
The elevation of published evidence as a source of authority has also empowered 
groups other than physicians to produce clinical practice guidelines, including hospital 
administrators, nurses, dieticians, and even patient advocacy groups. 
One interest group of particular importance in the formulation of clinical practice 
guidelines is the clinics themselves. Clinics, as well as individual departments within a 
hospital, have come to view clinical practice guidelines as documents that can be 
created essentially ad hoc, with rapid turnaround and limited resources, for use strictly 
within the institution that created them, rather than for promulgation to a wider audience. 
Given the limited goals of this type of clinical practice guideline, it is common practice to 
abridge the accepted standards for development of “official” clinical practice guidelines, 
such as might be produced by a national physicians’ professional association. For 
example, the clinic may decide to conduct a narrative (i.e. expert-focused) review of the 
literature rather than the more exhaustive systematic review. 
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As yet, scholars have published little research looking at whether these shortcuts 
materially affect the quality of intra-hospital clinical practice guidelines. If the conclusions 
of a clinical practice guideline based on a narrative review would be different from those 
based on a systematic review, the hospital may find itself with guidelines that conflict 
with later clinical practice guidelines developed under stricter standards, not to mention 
potentially harm patient outcomes. In this case study, we will examine one instance of a 
clinical practice guideline developed by the author at a community hospital using 
abridged standards, with particular attention to the abridged review process. By 
completing a counterfactual systematic review, we can isolate the influence of this single 
abridgement on the final clinical practice guideline and produce limited guidance for 
future clinical practice guidelines developed using this method. 
We should note that this case study does not address the ongoing problem of 
physician adherence to clinical practice guidelines and other attempts to standardize 
care decisions. The primary obstacle has been that all proposed solutions infringe to 
some degree on physician autonomy – the right of a physician to use his or her own 
standards and intuition to decide how to treat individual patients.[4] Since the subject of 
this case study is a clinical practice guideline developed and applied within a single 
institution, adherence was not a major challenge in the development process: all 
physicians covered by the clinical practice guideline are employed by the hospital, so the 
hospital can use its leverage as employer to ensure adequate compliance. 
 
Background: Clinical Practice Guidelines (CPGs) 
Developing a clinical practice guideline is a path many have trod before. The 
Agency for Healthcare Research and Quality hosts the US Guideline Clearinghouse, 
which lists summaries of 2,451 published clinical practice guidelines, along with 289 
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listed as “in progress.”[5] The UK’s National Institute for Health and Care Excellence, 
which is funded out of the budget for the National Health Service to provide guidance on 
quality and value for money in health care, hosts a compendium of rigorously-developed 
guidelines.[6] The Guidelines International Network, headquartered in Berlin, also lists 
over 6,700 clinical practice guidelines.[7] 
Who Publishes CPGs 
 International NGOs, such as the World Health Organization, for 
example. 
 National institutions, such as the National Institute for Healch and 
Clinical Excellence (NICE) in the United Kingdom, the United States’ Veterans 
Administration and National Institutes of Health, and Germany’s Ärztliches 
Zentrum für Qualität in der Medizin, among many others. 
 Physician’s and surgeons’ professional associations, for example 
the American College of Surgeons, the American Congress of Obstetrics and 
Gynecology, the American Thoracic Society, the American College of 
Rheumatology, the American Academy of Pediatrics, the American Academy of 
Family Medicine, and many others, including nursing and other provider 
associations such as the American and Royal Colleges of Nursing. 
 Academic institutions, especially academic medical centers. 
 Insurance companies ranging from the many Blue Cross/Blue 
Shield organizations to vertically integrated staff-model HMOs such as Kaiser 
Permanente, Group Health Cooperative of Puget Sound, Henry Ford Health 
System, and many others. 
 Broad stakeholder groups such as the National Quality Forum, 
whose guidelines member groups agree to adopt. 
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 Hospitals, especially quaternary academic medical centers or 
such systems as the Cleveland or Mayo Clinics. 
This long list does not include clinical practice guidelines developed for in-house 
purposes at hundreds of health care institutions nationwide; these are usually described 
as “institution-specific” guidelines. Groups at these institutions responsible for clinical 
practice guideline creation include administrators and physician specialty departments. 
Institution-specific CPG Development 
Institution-specific clinical practice guidelines are usually tailored specifically to 
the needs of the institution that develops them, because developing a clinical practice 
guideline is not without costs. The institution must convene a development committee 
(consisting of those who sign up out of interest as well as those who sign up out of 
obligation), it must compensate committee members for their time in addition to losing 
their productivity elsewhere, and it must overcome any resistance to producing the 
clinical practice guideline among those responsible for enforcing it. Accordingly, 
institutions consider multiple incentives when deciding which subjects merit the effort to 
develop a clinical practice guideline:[8] 
 Is a condition or disease highly prevalent in the population 
served? 
 Is a procedure overused or underused at the institution? 
 Is the cost of treating the condition or using the procedure high? 
 Is effective care available to treat the condition? 
 Are the procedure’s effects on mortality and morbidity unclear? 
 Do providers at the institution adhere to a standard of care for the 
condition or a standard of execution for the procedure? 
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 Is the standard in place at the institution at variance with a 
nationally promulgated standard? 
 Is there external pressure to reduce mortality and morbidity in a 
given area, e.g. from third-party payers, professional associations, or patient 
advocates? 
 Do existing guidelines recommend the use of a drug or medical 
device that the institution does not or cannot currently provide?  
Major centers of academic medicine, including those operated by the state, often 
produce in-house guidelines using the same rigorous development process as those 
designed for publication. At the other end of the spectrum, resource-limited institutions 
such as private clinics and small community hospitals may produce in-house clinical 
practice guidelines that incorporate very little original work. In most cases, these 
documents are alloys of published guidelines and other advisory material, such as 
“practice bulletins” published in professional research journals. Smaller hospitals that 
can still take advantage of residency and/or fellowship resources may compromise by 
conducting a limited or narrative review of the literature to answer questions about 
practice for which the hospital lacks a consensus opinion. 
Gold Standard for CPG Development 
The first standard definition of a clinical practice guideline was published in 1990 
by Field and Lohr, who defined it as “a systematically developed statement to assist 
practitioner and patient decisions about appropriate health care for specific 
circumstances.” [9] This definition was formalized by the Institutes of Medicine (IOM) in 
1992: “clinical practice guidelines are statements that include recommendations 
intended to optimize patient care that are informed by a systematic review of evidence 
and an assessment of the benefits and harms of alternative care options.”[10] 
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No extant studies or procedures dictate a gold standard for how an institution 
decides to begin the process to develop and/or implement a clinical practice guideline. 
As noted above, there can be many influences at work, so the decision remains strictly a 
judgment call by the developing institution. However, once that decision has been made, 
strict guidelines have been published governing the remainder of the process. The IOM 
has set eight standards to be followed by institutions developing clinical practice 
guidelines to ensure trustworthiness: [11] 
 Establish transparency in their methods 
 Manage any conflicts of interest prior to selection of group 
members 
 Be multidisciplinary, including all stakeholders as well as members 
of the public 
 Include well-designed systematic reviews that meet established 
standards 
 Use evidence-based rating systems to establish the strength of 
the evidence 
 Use clear and articulate language when publishing the 
recommendation 
 Incorporate external reviewers whose comments may remain 
anonymous 
 Have a planned updating system to keep current with the relevant 
literature 
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Some authors argue that these standards are sufficiently resource-intensive that 
only nationally funded institutions with a mandate to produce guidelines, such as NICE in 
the UK, are capable of producing high-quality guidelines in volume sufficient to support 
modern medical needs[12]. Smaller institutions experience significant difficulty balancing 
scientific rigor with real-world pragmatism[13]. 
Development Committee 
The institution should convene a committee of 8-10 people representing multiple 
disciplines [14], including: 
 Providers (doctors and nurses) with daily experience in treatment 
of the subject 
 Departmental chairs and other policy makers 
 Risk management representatives 
 Patient advocates 
 
At least half of the people on the committee should have prior clinical practice 
guideline development experience, public health credentials such as an MPH degree, or 
experience with critical literature evaluation from an EBP perspective. Information 
scientists may be present to perform the literature search. 
Once the committee is convened, it should review the issue(s) that triggered the 
formation of the committee and create a series of questions, arrived at by consensus, 
which the clinical practice guideline should answer. It should then nominate a 
subcommittee of 1-2 information scientists to conduct a systematic review of the 
literature in order to provide an evidentiary basis for answering these questions [15, 16]. 
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Conducting a Systematic Review 
Systematic reviews are designed to reduce bias and random error and are meant 
to assure that the resulting collation of data is scientifically valid. They summarize large 
bodies of evidence by synthesizing the findings of similar but separate studies.[17] The 
studies to be synthesized are often primary investigations, but can include prior 
systematic reviews. Usually the most robust studies for determining the effectiveness of 
a treatment are randomized controlled trials. A systematic review may include a meta-
analysis if one has been published that meets strong evidentiary criteria. Strategies for 
performing a systematic review were recently codified by the Institute of Medicine in 
Finding What Works in Health Care: Standards for Systematic Reviews.[16] 
In general, well-conducted systematic reviews begin by defining the means by 
which studies will be identified, included or excluded, evaluated, and aggregated. This 
requires the review subcommittee to develop a search strategy on the basis of the 
review questions created by the guideline committee. The subcommittee collects 
information from several core electronic databases, including  
 Cochrane Database of Systematic Reviews 
 MEDLINE (created and supported by the American National 
Library of Medicine) 
 EMBASE (a broad database including Medline and non-Medline 
sources, especially international and those with pharmaceutical foci); 
 CINAHL (the Cumulative Index of Nursing and Allied Health 
Literature); 
 PsycINFO, the comprehensive electronic archive of psychological 
literature, in the case of behavioral, substance abuse, or psychiatric topics. 
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The goal is to develop a search strategy that is sensitive enough to capture all 
relevant articles, but precise enough not to produce overwhelming results. Standard 
filters (e.g. language or species-specific exclusion criteria) may be used to narrow the 
field, although such filters may produce bias that the subcommittee should account for. 
The search results are then sieved in stages to exclude studies that the subcommittee 
identifies as outside the topic of interest or lacking sufficient evidentiary confidence. 
Typical sieve stages include a removal of articles with obviously inappropriate titles, or 
abstracts that show the article is inappropriate, before movement to assessment of full 
articles for all remaining results.  The subcommittee then reports out the remaining 
cohort of articles as the body of evidence to be evaluated by the committee.[15] 
Grading Review Results 
The next step is for the committee to designate a subcommittee of 1-2 people to 
assess the quality of the studies; this can be the same group that conducted the 
systematic review or a different group with greater experience in evidence assessment. 
Grading the data allows the guideline committee to flag poorly conducted studies for 
exclusion. Standardized grading tools also give the reader a transparent and easily 
accessible method for evaluating the strength of the evidence supporting the guidelines 
developed from the review. Several tools have been developed to assist the 
assessment, including 
 The Institute of Medicine’s Clinical Practice Guidelines We Can 
Trust 
 The U.S. Preventive Services Task Force’s recommendations for 
grading evidence in a tiered system (see Appendix 4) 
 The AGREE tool [18] 
 AGREE II [19] 
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The grading subcommittee then reports out grades/rankings of confidence for 
each study result in the cohort. 
Drafting the CPG Itself 
Once the systematic review of the literature has yielded graded results, the 
guideline development committee should examine the literature and write the first draft 
of the recommendation, choosing wording that expresses the strength of the 
recommendation. The committee should make revisions through consensus using either 
informal or formal procedures, depending on the size of the committee and the tone of 
the proceedings. The committee may identify the need for more research before voting 
on the final document and then optionally enter a validation phase, in which it invites 
external peer review and stakeholders to comment on the guidelines. Any corrections 
are made before final publication.[15] 
CPG Structure 
A clinical practice guideline should begin with a preamble that includes the 
following components: 
 Scope: To whom does the clinical practice guideline apply (for 
example, patients at this institution, patients in a given department, or patients 
nationwide)? 
 Target: Who is the audience for the clinical practice guideline (for 
example, practitioners, administration, or risk management)? 
 Background: What makes this topic of interest? 
 Introduction: Instructions on implementing the guidelines that 
follow 
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The main section should consist of a sequence of concrete recommendations, 
with each recommendation structured as follows: 
1. Title/topic 
2. Definition of terms (e.g. if the guideline concerns stillbirth, define 
stillbirth) 
3. Framing/exposition (Why is this issue important? What is the 
incidence/prevalence?) 
4. Level of confidence (see Appendix 3) 
5. One or more conditional statements (under these circumstances, 
take this action) 
6. Commentary, such as risks, benefits, harms, or alternatives to the 
recommended action 
Incentives to Use CPGs 
As the cost of health care to society rises, the incentive to ensure that these 
costs are paying for effective care increases. The US, for example, spent over $2.5 
trillion annually as of 2010 on health care and related expenses, and the figure rises 
each year.[20] Health care providers who have access to clear and specific guidelines 
are more likely to provide care that is appropriate, timely, and correct. [21] At the hospital 
level, producing and implementing clinical practice guidelines reduces the hospital’s risk 
of lost revenue via contested payment (such as Medicare rules that refuse payment 
when patients are readmitted) or malpractice penalties. 
Obstacles to CPG Acceptance 
Clinical practice guidelines seek to change professional behavior and institutional 
culture, a task as difficult to do as it sounds. The body of literature regarding 
implementation of guidelines is vast, and beyond the scope of this paper; however, 
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Pilling includes an excellent review.[17] Published research on guideline implementation 
demonstrates that change is possible, but the majority of interventions to support 
implementation have, at best, moderate effects.[22] Disseminating the guidelines is the 
first step; when a national body develops guidelines, it will usually disseminate them by 
publishing the results in the journal of the professional association as well as on an 
affiliated website. Motivating the changes to percolate through the profession is a harder 
task. Reminders to clinicians work best, followed by educational outreach, physician 
audit and immediate feedback mechanisms, which have more limited effects. The use of 
opinion leaders trails all other interventions. [22, 23] Complicating guideline 
implementation, of course, are the intricate organizations within which health care 
providers practice, and the inherent difficulty of changing a large system. Recently, 
electronic medical records have been developed to assist in clinical decision support, 
and these can be configured to remind physicians of institution-specific guidelines when 
appropriate. 
An important criticism of clinical practice guidelines is that the bodies that 
produce them fail to update them. A survival analysis conducted in 2001 found that 10% 
of guidelines were substantially incorrect within 3.6 years and 50% were out of date 
within 5.8 years [21, 24]. The primary obstacle to keeping clinical practice guidelines up 
to date is that the gold standard requires a systematic review of the literature to be 
performed for each update cycle; the results of this review must then be graded and 
analyzed. Since institutions may have difficulty mustering the effort and manpower 
required to fulfill these criteria every few years, many forgo the update process 
entirely.[25] Nevertheless, many handbooks and “guidelines for guidelines” continue to 
recommend that clinical practice guidelines be updated every 3 years.[26] 
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Case Study 
Lehigh Valley Health Network (LVHN) is a community hospital system located in 
Pennsylvania’s Lehigh Valley. LVHN partners with medical schools at the University of 
South Florida and Penn State University to provide clinical training opportunities for 
medical students. The system comprises three hospital campuses with 988 licensed 
acute beds, the 500-member Lehigh Valley Physician Group, and nine community health 
centers. The medical staff has more than 1,100 physicians representing 95 specialties, 
and LVHN is the area’s largest employer with more than 9,600 employees. In FY 2011, 
LVHN recorded over 65,400 admissions, 1.7 million outpatient visits, and 3,800 
deliveries. LVHN trains 278 residents in 17 residency and fellowship programs. The 
nursing staff comprises 2,334 registered nurses and has a 5 percent nursing vacancy 
rate. Individual departments at LVHN have developed 50 institution-specific clinical 
practice guidelines since efforts began in 2008.[27] Examples include Emergency 
Department algorithms for managing chest pain, burn triage, and guidelines for declaring 
brain death. 
In 2012, the OB/GYN department convened a CPG committee to establish 
clinical practice guidelines under the direction of a Maternal-Fetal Medicine (MFM) 
specialist on staff. The OB/GYN department at LVHN employs 45 physicians as well as 
an ever-growing number of physician extenders and mid-level providers. It also employs 
12 MFM specialists; these are board-certified OB/GYNs who have completed three 
additional years of fellowship training in managing high-risk pregnancies. An MFM 
specialist is present in the hospital at all times to provide patient care and train residents. 
LVHN’s Development Committee 
The OB/GYN departmental CPG committee is a standing committee that meets 
monthly and is tasked with identifying areas in which clinical practice guidelines are 
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needed as well as all guideline production within the department. The committee roster 
consists of 20 members: 10 attending physicians (2-3 from each private practice), 2 
resident physicians (one of whom is the author of this paper), 5 in-patient nurses, 2 risk 
management representatives, and the department chair. Although this total is over twice 
the number recommended by Shekelle et al. for optimal consensus formation, members 
are not expected to attend all committee meetings, so the number present at any given 
meeting is likely to approximate the ideal number.[14] Ideally, patient and public 
involvement should be included as practice guidelines that affect them are adopted, but 
this committee does not include those representatives. 
The de facto leaders of the committee are the medical director of the department 
and the MFM specialist who suggested and convened the committee. They expect that 
the committee’s methodology for development and implementation will become more 
robust as experience develops, but the committee has no mechanism in place to assure 
that it does. 
The CPG committee has initiated, developed, reviewed, adopted, and 
disseminated three guidelines to clinical stakeholders; seven additional topics are under 
development. The guidelines that have been adopted have several goals in mind, 
including enablins providers at all levels of training to understand expected standards of 
care, providing emergency reference material, and providing critical data about specific 
OB/GYN topics in the most useful and accessible form.   
CPG Development Process 
1. LVHN has dictated that the committee must produce one clinical 
practice guideline each year in the subdisciplines of obstetrics, gynecology, and 
gynecological oncology. 
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2. The committee selects an area in which a new clinical practice 
guideline is needed by considering the standard factors (see “Institution-specific 
CPG Development” above) 
3. An informal consensus is achieved; unanimous agreement is 
desired but not mandatory 
4. Members of the committee with expertise in the chosen area 
develop a list of specific questions that the new guideline must address 
5. A committee member is assigned to author the guideline 
6. The guideline author may choose the literature to include in their 
narrative review themselves or the literature may be suggested by the leaders of 
the committee 
7. The guideline author conducts a narrative review, collates the 
information, and drafts the guideline 
8. The two committee members with the most expertise relevant to 
the topic review the draft and suggest revisions or additional research to include 
9. The guideline author revises as needed and returns the second 
draft to the committee at large 
10. The committee discusses the draft guideline and suggests further 
revisions 
11. The guideline author revises the guideline as needed and 
produces a final draft 
12. The committee conducts a formal vote to adopt the guideline 
13. The guideline is published to an internal LVHN website and e-
mailed to all members of the department 
14. All clinicians in the department sign an agreement that they have 
read and understood the new guideline 
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15. The guideline author is responsible for continual review of the 
literature pertinent to their guideline, usually within 2 years 
16. The committee schedules review of each clinical practice 
guideline after 3 years 
Case Study CPG: Late Preterm and Early Term Indications for Delivery 
Guideline 
Background 
Preterm birth rates continue to rise in industrialized countries, despite preterm 
birth causing significantly increased risks of neurodevelopmental disabilities and infant 
morbidity and mortality. One reason for this rise is that many preterm births are 
iatrogenic, i.e. induced or initiated by a health care provider. Because we know so much 
now about pregnancy complications and their high risks, this is intentional: the provider 
is making a judgment call that the harm caused by the preterm birth is preferable to the 
risk of some greater harm that may be caused by allowing pregnancy to continue[28].  
 
Substantial literature supports the increase in iatrogenic infant morbidity 
associated with early birth, with some studies showing late preterm births now reaching 
as much as 32% of all births, but Joseph and D’Alton argue that there is a “sound 
theoretical and empirical basis for medically indicated preterm delivery”[29]. They 
emphasize that there are several situations when early delivery is clearly preferable to 
continuing the pregnancy, even if the infant’s first weeks of life are spent in the neonatal 
intensive care unit (NICU).  These so-called “hard” indications for iatrogenic birth 
include: 
 Severe preeclampsia 
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 Intrauterine growth restriction, with abnormal fetal testing 
demonstrating decreasing physiological reserves 
 Acute placental abruption 
Usually delivery is recommended as soon as the condition is diagnosed. 
Similarly, delivery at 32-34 weeks for monoamniotic/monochorionic twins is 
recommended, as the risk of intrauterine fetal demise increases substantially after this 
gestational age [30, 31]. However, experts disagree, and data can be scarce or 
conflicting, regarding what the potential harms are and how to calculate risks when 
iatrogenic preterm birth is being considered in the absence of these indications [32, 33]. 
Choosing a Subject 
Although LVHN had not developed a formal clinical practice guideline governing 
“hard” indications for preterm delivery, the committee felt that a satisfactory standard of 
care was being followed by providers and that widespread agreement already existed 
among providers as to the proper diagnoses and responses governing these indications. 
Consequently, the committee opted to focus instead on so-called “soft” indications.   
 
At the beginning of guideline development, MFM specialists developed a list of 
indications, based on their extensive clinical experience, to include in the guidelines. Soft 
calls are harder for providers to make; the committee needed to collect outcome data 
from good literature to be able to recommend appropriate action, knowing the risks of 
early delivery. The following nine indications were chosen by consensus for inclusion in 
the clinical practice guideline: 
 
1. Hypertension-related indications: 
a. Gestational hypertension 
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b. Mild preeclampsia 
c. Preeclampsia superimposed on chronic hypertension 
2. Fetal anomalies 
3. Placenta accreta 
4. Diabetes 
5. Previous classical incision or myomectomy 
6. Oligohydramnios 
7. Placenta previa 
8. Previous stillbirth 
9. Uncomplicated multiple gestation 
 
Assigning a Guideline Author 
The author of this paper volunteered to undertake all tasks required to draft the 
guideline as part of this larger case study. 
Narrative Review 
A narrative review of scientific literature is distinguished from a systematic review 
in that, while both reviews strive to include all relevant literature for a given topic, a 
systematic review is required to state and follow stringent rules regarding the search for 
evidence; it must also reveal how the decisions were made about relevance of studies 
and the validity of the included studies. By contrast, a narrative review is not required to 
state or follow rules regarding the sieving or classification of evidence. This type of 
review includes reviews of a subset of literature that is determined arbitrarily, e.g. by only 
looking in certain journals or by accepting a predetermined list compiled by a third party. 
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I performed a narrative review of the literature, looking for delivery 
recommendations for the nine indications listed above. The committee chairperson 
recommended fifteen articles to me.[29, 31-44] I identified further articles from the 
references and reviewed practice bulletins published in the journal of the American 
Congress of Obstetricians and Gynecologists (ACOG)[45-48]. ACOG practice bulletins 
are developed by expert committees to guide and standardize clinical practice among 
OB/GYNs, but are not intended to meet the standards of evidence required of a clinical 
practice guideline. 
Process Results 
I reviewed the articles and composed a draft clinical practice guideline based on 
the evidence obtained from the articles. For ease of practitioner use – since ease of use 
was one of the major criteria for a clinical practice guideline to be approved by the 
committee – I also created a Working Summary of the Clinical Practice Guideline (for 
these two documents, see Appendix 1 and 1a). 
Following the workflow outlined above, MFM specialists reviewed my draft 
guideline and I revised it according to their suggestions. Upon submission of the second 
draft to the committee at large, the committee voted to adopt the guideline as written. 
Divergence from Gold Standard 
Although LVHN’s OB/GYN department has greater resources to devote to 
development of clinical practice guidelines than a private clinic, it is nevertheless 
constrained by a number of circumstances: 
 No LVHN employees are compensated for time spent working for 
a committee 
 Certain job categories at LVHN require participation in a 
committee 
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 No potential committee members are formally trained in 
information science 
 All potential committee members have full-time jobs, mostly 
providing patient care 
 
These resource constraints led to a number of practices that were at variance 
with the gold standards enumerated earlier: 
 Some committee members were on the committee simply to fulfill 
institutional requirements and did not have a direct stake in the outcome 
 The committee did not include: 
o Reviewers from outside the department 
o Patient advocates 
o Information scientists 
 The guideline author was directed to gather evidence via narrative 
review instead of systematic review 
 The guideline author was directed not to formally grade the quality 
of studies identified in the review 
 Periodic updating of the guideline is nominally planned, but no 
process is in place to trigger, produce, or review any updates 
Implementation and Aftermath 
Indicated Late Preterm and Early Term Birth was adopted by the CPG 
Committee in December 2012 and implemented in January 2013 by widespread 
consensus. Practicing clinicians were required to read and understand the new 
recommendations. Assessing whether or not clinicians follow the guidelines is an 
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obvious next step in guideline evaluation. Some estimate that clinicians practice firmly 
within evidence-based clinical decision-making only 55% of the time.[22, 49, 50] 
At LVHN, this problem is partially overcome by corporate decree. LVHN is a 
public hospital; all employees must follow the hospital’s rules or risk their livelihood. The 
hospital has given departments power to regulate their own clinicians, and the OB/GYN 
department has decided that the CPG committee’s recommendations are to be followed. 
Therefore, individual clinicians, who have already bought into the system by virtue of 
their employment, are professionally bound to follow the guidelines. The risk 
management department ensures adherence through QA sessions in the case of poor 
outcomes. 
A more subtle reason that clinical practice guideline implementation may be 
easier at LVHN than elsewhere is that the MFM team has been given a special 
hierarchical status in the department’s internal culture. Even with their own private 
patients, clinicians will defer to an MFM’s judgment. The CPG committee is endorsed 
and managed by the MFM specialists, and therefore most clinicians buy into the 
recommendations that emerge from the group. 
The CPG committee also contains other stakeholders, which is a key part of 
creating guidelines that are acceptable to those meant to be following them. An 
important barrier to guideline implementation is the problem of handing guidelines down 
from on high and expecting practitioners in a fiercely autonomous profession to adopt 
them. Arguably, by including stakeholders from multiple strata of practice, good CPGs 
have a smaller hurdle to overcome to achieve wide implementation. [20] 
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Counterfactual Systematic Review 
Introduction 
The purpose of this part of the case study is to shed light on the effect that the 
variance from gold standard practices had on the final clinical practice guideline. The 
best way to analyze these effects is to isolate them by replicating the development 
process using gold standard practices and then to compare the results. Since it would be 
infeasible to assemble an entire counterfactual committee, I have focused instead on the 
latter half of the variant practices: 
 Narrative review instead of systematic review 
 No formal grading of the literature identified 
By completing a counterfactual systematic review, using the literature available at 
the time, and by formally grading the literature according to gold standard grading 
systems, I was able to make the closest comparison of the actual guideline to a 
hypothetical ideal guideline that was possible under the circumstances. 
Methods 
The question that this systematic review intended to answer is  
 
“When is the optimal time for delivery in pregnancies complicated by: 
prior stillbirth, placenta accreta, stable placenta previa, vasa previa, gestational 
hypertension, preeclampsia (mild and severe), multiple gestation, prior classical 
Cesarean, prior myomectomy, fetal anomalies, oligohydramnios, and diabetes 
(gestational, pregestational)?”  
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Because a randomized controlled trial would be unethical and unacceptable 
when fetal death is a likely outcome, retrospective reviews have been used to determine 
the best possible gestational age at which to plan delivery in high-risk pregnancies. I 
included other clinical practice guidelines in my search as well. Appendix 2 includes the 
full search parameters. 
 
The initial search was performed on March 5, 2013 and resulted in 786 articles. 
The following standard filters culled the data to 513 articles: 
 Abstract and full-text available 
 Humans 
 English 
This cohort was further refined on title alone to include 55 articles. Criteria 
resulting in exclusion included: 
 Case reports 
 Editorials and letters 
 Research performed outside of Western Europe, Australia, and 
North America 
To be included, titles needed to indicate that the article addressed timing of 
delivery, outcomes, complications or delivery within the gestational age the CPG 
includes. Titles were also rejected if the article mainly addressed spontaneous preterm 
labor. Culling abstracts of articles further reduced the articles to a final number of 30. 
These 30 papers I reviewed in full to discover if they made recommendations about 
optimal time of delivery; if not, I noted why they did not. 
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Table 1.  Summary of Articles by Recommendation and Type 
 
Identifiers Condition  Recommendation? Agree? 
Quality of 
Evidence 
Guideline 
Evidence 
Level 
Article 
Type 
21962629 Gest HTN ≥ 37 wks Yes I 
 
Analysis 
(sec) of 
RCT 
RCOG 
(NoPMID) Previa 38wks Yes  I Level A Guideline 
[RCOG 
(NoPMID)]* Acreta 36-37wks Yes I Level A 
[Guideline
] 
22220321 HTN ≥ 38 wks Yes I Level A Guideline 
21962624 Prior ut incs ≥ 39 wks Yes II-A Level B Guideline 
19300347 Prior stillbirth ≥ 39 wks Yes III Level C Guideline 
15738045 Pregest DM By due date Yes I Level A Guideline 
22855972 Mult gest 38 wks Yes I Level A Guideline  
21962631 Prior stillbirth ≥ 39 wks Yes II-A 
 
Lit 
review/ex
pert 
consensus 
[21962627]* Mult gest 38 wks Yes III 
 
[Lit 
review/ex
pert 
consensus
] 
21962628 Oligohydramnios ≥ 34 wks Yes III 
 
Lit 
review/ex
pert 
consensus 
21962625 IUGR 37-38 wks singl Yes II-B 
 
Lit 
review/ex
pert 
consensus 
21962625 IUGR 34-36 wks TIUP 
   
Lit 
review/ex
pert 
consensus 
21962626 Fetal anomalies Case-dependant Yes I 
 
Lit 
review/ex
pert 
consensus 
21962623 Accreta 34-35 wks Yes II-A Level B 
Lit 
review/ex
pert 
consensus 
16401210 Mult gestation 32-34 wks Yes II-A 
 
Literature 
review 
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21962630 DM Case-dependant Yes I 
 
Literature 
review, 
expert 
consensus 
10879335 Mult gest ≥ 38 wks Yes II-B  
Retrospec
tive 
cohort  
22302586 Mult gest ≥ 36 wks No II-B   
Retrospec
tive 
cohort  
16801956 HTN 39wks  Yes II-B  
Retrospec
tive 
cohort  
16801956 DM 40-41 wks  II-B  
Retrospec
tive 
cohort  
21585638 Multiple gest 32 wks Yes II-B  
Retrospec
tive 
cohort  
11228502 Mult gest 37-38 wks Yes II-A   
Retrospec
tive pop 
SOURCE:  literature search by author conducted on 3/5/13-3/8/13. See appendix for full details 
of search strategy and full search results. 
*One guideline and one literature review examined two conditions and made a recommendation 
for each.  Their recommendations are presented on two separate rows for ease of review, but 
they are not separate articles. 
 
 
I also graded the literature based on the USPSTF grading system and the ACOG method of 
grading recommendations. (See Appendix 3) 
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Results 
Of the 30 full-text articles reviewed, 20 gave recommendations for optimal time of 
delivery. Of these 20, all agreed with our guideline’s recommendations, for a total agreement of 
100%. All 20 papers were also published before the original narrative review took place, thus 
avoiding any problems of anachronism when comparing the two reviews. 
 
Discussion 
As a first-year resident physician in the OBGYN department, I was eager to become 
involved in delivering patient care. I found – and this experience is common to newly-minted 
doctors – that although much of the standard patient care we were expected to provide had its 
roots in evidence-based medicine, the existing culture of LVHN exerted substantial influence on 
clinical decisions, particularly when there was perceived to be no single method that far 
outperformed the others. Many different providers translated into slightly divergent standards of 
care. “Going to the data” to clarify best practices was often a daunting task, due to the wealth of 
data available and the sometimes conflicting or unclear recommendations derived from that 
data. However, in medical school, we are taught to be life-long learners, and a clear 
assessment of the current data and standard best practices is exactly the kind of thing we have 
been trained to do. 
 
Late preterm and early term birth increases the risk of perinatal morbidity and long-term 
disabilities. To deliver early, therefore, and risk the associated iatrogenic morbidity, a clinician 
must feel comfortable that she has strong reasons. Such certainty is hard to come by. The 
evidence-based literature provides us with information we can use to make educated guesses, 
taking account of the risks and benefits of our decisions.   
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As I began this case study, my training had biased me to assume that without a full and 
time-intensive systematic review of the literature, the clinical practice guidelines we developed 
would be at best incomplete and at worst harmful for having ignored or missed important 
evidence.  My review of the policy literature and the results of the systematic review I completed 
have shown me that our process for guideline development was not unusual for smaller 
institutions. Nor were the results so horribly off-base. Although we did not account for bias, this 
is a fundamental flaw that can be addressed only through full review of the literature, both 
published and unpublished, in all languages and across all countries – a feat that is often 
impossible in practice for any institution.  
 
Shekelle and colleagues assessed whether current clinical practice guidelines in practice 
are up-to-date, and found that a distressing proportion of national guidelines were not [51, 52]. 
Browman points out that Shekelle’s method may have been the important conclusion to 
his article – specifically, that there are practical obstacles to achieving perfection (or close) in 
guideline development. A possible solution may be a process that starts with a methodologically 
strong literature review that would build a “foundation” guideline, one that met all possible 
criteria of trustworthiness. Then, future updates – Thompson’s “aftercare” of the guidelines – 
could be more easily limited to a focused literature search and the guidance of experts. Shekelle 
suggests guidelines be revised every three years. 
 
In effect, this is how Indicated Late Preterm and Early Term Birth was born. We started 
from several national medical guidelines (the ACOG Practice Bulletins). We then had expert 
guidance about which indications were important and an expert-focused narrative review of the 
literature regarding these indications. A counterfactual systematic review with language and 
geographic limitations has been shown to back up our conclusions. Given the significant 
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emphasis placed on systematic reviews as critical to the development of guidelines, it is 
interesting that we did not need to perform a more thorough review of the literature to reach the 
same conclusions for these clinical questions. 
 
Perhaps the lack of discrepancy between narrative and systematic review is specific to 
the particular questions. A clinical problem with a more robust body of ongoing literature (e.g. 
asthma) and higher population prevalence might benefit from frequent and detailed review of 
new literature. Perhaps these particular clinical questions don’t have enough current research to 
change the management; the studies that are available are purely retrospective. Published 
research about high-risk pregnancies tends to take a very conservative approach because the 
results of a less-conservative management plan can be so disastrous; if a baby is delivered 
early and there are complications of prematurity, providers may console the patient and 
themselves that at least the baby is not an intrauterine fetal demise. There are many 
retrospective and observational studies, but they all agree with each other and all qualified their 
recommendations with words like “presumably,” “apparently,” and “seems reasonable to.” Thus, 
it is possible that the study of high-risk pregnancy is an outlier: studies tend to show similar 
results because study designs tend to be conservative and reflect only retrospective analyses of 
conventional care, rather than experimental care that intentionally breaks with convention and 
might produce innovative (but possibly deadly) results. 
 
Despite initially finding frightening the idea that we did not need to perform a full 
systematic review to make an accurate recommendation, I am rethinking this assumption [13, 
51, 53]. We know that making gold-standard guidelines is expensive in time, training, talent and 
institutional resources. It requires significant attention to minimizing biases. It requires attention 
to conflicts of interest and multidisciplinary committee membership. However, if we can come up 
with a viable method for practical guideline creation and show that the method is valid, perhaps 
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we needn’t limit ourselves to poor guidelines or no guidelines in the real world. If, for instance, 
we take Shekelle’s work as a good place to start, and develop guidelines based on a foundation 
of excellent evidence with frequent updates to save our guidelines from languishing, forgotten, 
as the literature marches on without them, we can make headway into guidelines for the rest of 
us. 
Conclusion 
Published literature regarding the development of EBP-oriented clinical practice 
guidelines has always stressed the need to begin with a systematic review. In some cases, the 
authors of these papers have argued that guidelines developed without systematic review are 
worse than no guidelines at all [1, 12, 20]. So health care providers seem to have two options: 
develop guidelines using the resource-intensive, slow, gold standard process or use no 
guidelines at all and rely on each provider to review the literature individually (during their free 
30 seconds per article per day, naturally). However, this case study superficially appears to 
demonstrate that a guideline developed using a narrative review could be just as good as one 
developed using a systematic review. What explains the discrepancy? 
One easily overlooked explanation is that the guideline developed in this case study was 
an iterative guideline, i.e. it relied strongly on practice bulletins that had previously been 
published by a national institution (ACOG) that itself used systematic review. This enabled the 
committee specialists to select only notable literature that they felt added to the perspective 
found in the practice bulletins. The fact that a counterfactual systematic review accorded with 
the narrative review in all significant aspects indicates what might be termed a potential third 
way: guidelines developed via narrative review that bootstrap from one or more existing 
systematic reviews. 
In order for this third option to be viable, certain conditions need to be met: 
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 The CPG must incorporate one or more “foundational” guidelines that 
were compiled using systematic reviews that were exhaustive and methodologically 
sound. 
 The development committee must have at least one member who has 
working knowledge of significant published research in the years since publication of any 
foundational guidelines (those satisfying the above criterion). 
 The development committee must have at least one member who has 
training or experience in formal grading of evidence from an EBM perspective. 
 Development committees may profit from assuring that representatives of 
cross-cutting or overlapping disciplines are participating in the development effort.  In 
this case, the perspectives of a neonatologist may have been helpful. 
 The institution must schedule and execute updated narrative reviews 
every three years under these same conditions. 
 In addition to regular updates, the institution must assure that it has a 
mechanism in place to monitor and respond rapidly to new developments in the 
literature. 
 
If these conditions are obtained, an institution could use a development process similar 
to the one described in the case study and possibly emerge with a clinical practice guideline that 
exhibited a high degree of correlation with a hypothetical gold standard guideline covering the 
same material. If this occurred, it would encourage more institutions to attempt development of 
more guidelines, contributing to an overall improvement in patient care. On the other hand, the 
specific circumstances of this case study, as discussed earlier, may render it an outlier, unable 
to offer predictive power about guideline development in other specialties. 
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It should also be possible to extend this case study by evaluating the success of practice 
change after guideline implementation.  Clinical practice guidelines have had moderate success 
in changing practice in some situations. Gibbins et al. recently reported success in implementing 
new OB guidelines[54]. They also measured, over several months, how practice management 
successfully changed in their institution after implementation. Perhaps LVHN can also change, 
despite the frequent literature findings that discourage such a possibility. The practice 
population in the Gibbins study is similar to that at LVHN, and the project is likely to be 
generalizable. Such a study is well within the scope of a resident research project. 
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Appendix 1 
 
 
 
Lehigh Valley Health Network 
 
PATIENT CARE SERVICES 
PATIENT CARE MANUAL 
CLINICAL PRACTICE GUIDELINE 
 
Indicated Late Preterm and Early term Birth 
 
I. KEY POINTS 
 
1. A large proportion of neonatal morbidity and mortality is secondary to  
preterm delivery (prior to 37 weeks gestation). 
2. The majority of neonatal complications are seen in neonates born 
before 34 weeks, however data has recently shown numerous 
respiratory and other complications in late preterm (34-37 weeks) and 
even in early term births (37-39 weeks).   
3. True indications for late preterm or early term delivery include severe 
preeclampsia, intrauterine growth restriction (IUGR) with abnormal 
fetal testing, and acute placental abruption.  
4. Conditions for which the optimal timing of delivery is debatable include 
prior fetal demise, stable placenta previa/accreta, mild preeclampsia or 
gestational hypertension, multiple gestations, prior classical 
hysterotomy or myomectomy, fetal anomalies, maternal medical 
conditions including diabetes and cholestasis, IUGR with reassuring 
fetal testing, and alloimmunization in pregnancy. 
  
 
I. SCOPE: 
 
This clinical practice guideline (CPG) applies to all pregnant women cared 
for at Lehigh Valley Health Network.  It represents recommendations, not 
binding standards and reflects the most recent recommendations. 
 
II. SKILL LEVEL: 
 
Obstetricians, Certified Nurse Midwives under the direction of an 
Obstetrician, Obstetrical residents. 
 
III. INTRODUCTION/PURPOSE: 
 
Definitions: 
 42 
 
 Preterm Birth: Birth before 37 weeks gestation. 
  Late Preterm Birth: Birth between 34 0/7 weeks and 36 6/7 weeks 
gestation. 
Early Term Birth: Birth between 37 0/7 weeks and 38 6/7 weeks 
gestation. 
 
Preterm birth occurs in approximately 12% of all pregnancies, however 
contributes to a large proportion of neonatal morbidity and mortality.  
Although recently there has been a slight decrease in overall rate of 
preterm birth, the rate of late preterm birth is steadily increasing.  Late 
preterm birth has been associated with numerous neonatal complications, 
including respiratory distress syndrome, transient tachypnea of the 
newborn, pneumonia, respiratory failure, surfactant use, ventilator use, 
sepsis, hyperbilirubinemia, interventricular hemorrhage, and necrotizing 
enterocolitis.  Long term data has shown that cerebral palsy, mental 
retardation, and developmental disabilities are significantly more common 
in infants born in the late preterm period when compared to term. 
 
Similarly, early term birth has been associated with increased rates of 
these same complications, including neonatal death.  These complications 
lead to more neonatal intensive care unit (NICU) admissions and longer 
hospital stays for the infant. 
 
Some late preterm and early term births occur due to spontaneous 
preterm or term labor, and are therefore unavoidable.  Many late preterm 
and early term births are considered to be “indicated”.  True indications 
would include severe preeclampsia, intrauterine growth restriction (IUGR) 
with abnormal fetal testing, and acute placental abruption.  There are a 
number of other indications for which the optimal timing of delivery is 
debatable.  These include prior fetal demise, stable placenta 
previa/accreta, mild preeclampsia or gestational hypertension, multiple 
gestations, prior classical hysterotomy or myomectomy, fetal anomalies, 
maternal medical conditions including diabetes and cholestasis, IUGR with 
reassuring fetal testing, and alloimmunization in pregnancy. 
 
The purpose of this guideline is to determine the optimal timing of delivery 
for the above-mentioned debatable indications for late preterm/early term 
birth. 
 
IV. GUIDELINES 
 
A.  Previous Stillbirth  
 
 Definition: Stillbirth: Death of a fetus at 20 or more weeks gestation. 
 
 Background 
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o Overall rate of stillbirth recurrence is between 0-8%. 
o The highest risk is associated with an earlier gestational age 
of the stillbirth, more than one prior stillbirth, stillbirth 
associated with IUGR, and in non-Hispanic black women. 
o Lower risk if prior stillbirth was unexplained. 
o Women with a prior stillbirth have increased risk of adverse 
pregnancy outcomes in subsequent pregnancies, including 
preeclampsia, placental abruption, IUGR, preterm birth, and 
cesarean delivery. 
o Prospective fetal mortality rates do not significantly increase 
until after 40 weeks gestation. 
o No clear evidence that iatrogenic late preterm or early term 
birth reduced the rate of recurrent stillbirth. 
 
 Timing of Delivery Guidelines (Level III) 
o Elective delivery at 39 weeks gestation.  
o Elective delivery between 37-38 6/7 weeks if earlier delivery 
is strongly preferred by the patient AND fetal lung maturity is 
documented by amniocentesis.  
 
B.  Known Placenta Accreta  
 
 Definitions:  
o Placenta Accreta: Abnormal placental attachment such that 
the chorionic villi attach to myometrium rather than being 
restricted to the deciduas basalis.  
o Placenta Increta: Chorionic villi invade the myometrium 
o Placenta Percreta: Chorionic villi invade through the 
myometrium 
In this guideline, the general term accreta will refer to all three 
grades of these abnormal placental attachments. 
 
 Background 
o Greatest risk is maternal hemorrhage – accreta is associated 
with large volume postpartum transfusions, as well as 
significantly increased risk of peripartum hysterectomy.  
o Strongly associated with placenta previa and prior uterine 
surgeries. Increasing incidence parallels increasing 
cesarean section rate. 
o Maternal mortality reported as high as 5.6% in some studies 
o Diagnosed by U/S and/or MRI, though only 2/3 cases known 
prior to delivery 
o Less dangerous to fetus than to mother- in absence of 
maternal bleeding, data does not support increased fetal 
mortality or IUGR 
o Incidence of maternal bleeding beyond 39 weeks is 93% 
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o 44% rate of emergency delivery <36 weeks for maternal 
hemorrhage in recent study 
 
 Timing of Delivery Guidelines (Level III) 
o Planned delivery via cesarean section at 34-35 weeks, with 
or without FLM testing 
o Goal is to avoid emergency cesarean hysterectomy 
 
   C.  Stable Placenta Previa  
 
 Definition: Placenta Previa: Placenta that overlies or is proximal to 
the internal cervical os 
 
 Background 
o Greatest risk is maternal hemorrhage and associated 
consequences: transfusion, peripartum hysterectomy, DIC, 
ICU admission and death. 
o The presence of a previa  at the time of delivery is an 
indication for cesarean section to avoid maternal 
hemorrhage.  
o It is often a cause of iatrogenic preterm delivery secondary 
to bleeding or preterm labor. 
 Approximately 17% of women with placenta previa 
deliver <34 weeks, a rate that increases to 45% if 
midtrimester cervical length <3cm. (Includes both 
iatrogenic and spontaneous delivery) 
o The advantage of earlier delivery is a decreased probability 
that a patient will present with acute hemorrhage and require 
an emergent cesarean delivery.  This may reduce the risk of 
surgical complications. 
o Major clinical decision requires weighing the benefits of 
avoiding emergent delivery against neonatal risks of 
prematurity. 
 
 Timing of Delivery Guidelines (Level III) 
o In a stable patient- Planned delivery between 36-37 weeks 
with documented fetal lung maturity by amniocentesis or at 
38 weeks without an amniocentesis. 
o In a patient with comorbidities (Obesity, multiple prior 
cesarean sections) or who has had multiple antepartum 
episodes of vaginal bleeding- Scheduled delivery between 
36-37 weeks without amniocentesis. 
 
D.  Vasa Previa 
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 Definition: Vasa previa:  Obstetric condition characterized by fetal 
vessels that traverse the membranes located over the internal 
cervical os and thus in advance of the fetal presenting part.  
 
 Background: 
o Main risk in vasa previa is rupture of the fetal vessels, which 
can occur with or without membrane rupture.  This can result 
in fetal exsanguinations in a very short period of time. 
o In monochorionic twin gestations, the perintal mortality is 
high for both twins, even if the vasa previa is associated with 
only one twin, due to the presence of placental vascular 
anastomoses. 
o The fetal vessels are also at risk of compression from the 
fetal presenting part since they are not protected by the 
umbilical cord. 
 
 Timing of Delivery Guidelines (Level III) 
o Cervical length ultrasound should be performed between 33-
34 weeks 
o If cervical length >2.5cm, planned delivery at 36 weeks 
without amniocentesis 
o If cervical length <2.5cm, planned delivery at 34-35 weeks 
without amniocentesis. 
 
 
E. Mild preeclampsia/Gestational HTN  
 
 Definitions: 
o Mild Gestational Hypertension: Systolic blood pressure ≥140 
mmHg and/or diastolic blood pressure ≥90 mmHg in a 
previously normotensive pregnant woman who is ≥20 weeks 
of gestation and has no proteinuria 
o Severe Gestational Hypertension: Sustained elevations in 
systolic blood pressure ≥160 mmHg and/or diastolic blood 
pressure ≥110 mmHg with no proteinuria. 
o Mild Preeclampsia: New onset of hypertension (≥140/90 
mmHg)  and proteinuria after 20 weeks of gestation in a 
previously normotensive woman. 
o Severe Preeclampsia: Sustained elevations in systolic blood 
pressure ≥160 mmHg and/or diastolic blood pressure ≥110 
mmHg with severe proteinuria (>5g), or other 
signs/symptoms of end-organ injury present 
 
 Background 
o Infants born to hypertensive women have increased risks of 
admission to the neonatal intensive care unit, longer hospital 
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stays, and higher rates of respiratory distress syndrome 
(may be related to higher rates of IUGR). 
o Risks of expectant management between 34-37 weeks 
gestation include progression to severe hypertension, 
eclampsia, HELLP syndrome, placental abruption, 
pulmonary edema, fetal growth restriction, and fetal death. 
o There is no data to support that expectant management 
between 34-37 weeks improves perinatal outcomes or 
increase maternal/fetal risks. 
o HIPITAT trial (Induction of labor versus expectant monitoring 
for gestational hypertension or mild preeclampsia after 36 
weeks gestation) 
 Multicenter randomized controlled trial 
 Induction at >36 weeks was associated with reduction 
in composite outcome of HELLP syndrome, 
pulmonary edema, placental abruption, eclampsia, 
maternal ICU admission, and cesarean delivery 
 No difference in neonatal outcomes between two 
groups (perinatal death, 5-minute Aprag <7, Cord Ph 
<7.05, NICU admission, and respiratory distress 
syndrome). 
 
 Timing of Delivery Guidelines (Level I) 
o Severe gestational hypertension and severe preeclampsia-
>34 weeks (for diagnoses made at or after 34 weeks). 
o Mild gestational hypertension and mild preeclampsia- >37 
weeks 
 
 
F.  Multiple Gestation  
 
 Definition:  Multicystic encephalomalacia:  Cystic lesions in the 
cerebral white matter of areas supplied by the anterior and middle 
cerebral arteries, associated with profound neurologic 
abnormalities. 
 
 Background 
o Multifetal gestations carry a number of perinatal risks, 
including low birth weight, preterm delivery, cerebral palsy, 
neonatal and infant death, respiratory distress syndrome and 
longer hospital stay.  These risks vary based on type of 
multiple gestation. 
o Dichorionic twins 
 Risk of stillbirth at 39 weeks exceeds that of a post 
term singleton pregnancy. 
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 Twins at 37-38 weeks have stillbirth rates similar to 
post term singleton pregnancies. 
o Monochorionic-diamniotic twins 
 Risk of stillbirth and other perinatal complications is 
higher compared to dichorionic pregnancies. 
o Monochorionic-monoamniotic twins 
 Risk of stillbirth of both fetuses is 10-20%.  This is 
most often due to consequences of cord 
entanglement, which occurs in most cases.   
 Management prior to delivery can include close 
outpatient surveillance (NST’s 2-3 times a week) or 
inpatient surveillance (NST’s multiple times a day or 
continuous monitoring).  There are insufficient data to 
determine which strategy is better, though recent 
observational data suggests that some amount of 
inpatient monitoring may decrease fetal mortality. 
o Single-Twin Intrauterine fetal demise (IUFD) 
 Occurs in 0.5-6% of twin pregnancies and can have 
significant sequelae on the surviving fetus. 
 Sequelae include:  
 Multicystic encephalomalacia and/or 
multiorgan damage in 20-30% of 
monochorionic pregnancies  
 Preterm labor and delivery in all twin 
pregnancies (no increased risk of infection but 
higher rates of cesarean delivery due to 
nonreassuring fetal status of surviving twin). 
 Maternal consumptive coagulopathy (very 
uncommon if baseline maternal hematologic 
studies are normal). 
 
 Timing of Delivery Guidelines (Level III) 
o Dichorionic twins  
 Elective delivery at 38 weeks gestation in well-dated 
and uncomplicated dichorionic pregnancies 
 If the patient desires prolongation of pregnancy past 
38 weeks, there must be evidence of normal fetal 
growth, amniotic fluid, umbilical artery Doppler 
studies, and twice weekly antenatal testing (at least 
one biophysical profile). 
 Prolongation past 39 weeks gestation is not 
recommended due to increased risk of stillbirth 
without anticipated neonatal benefit. 
o Monochorionic-Diamniotic Twins  
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 Elective delivery between 36-37 weeks in well-dated 
and uncomplicated monochorionic-diamniotic twin 
gestations. 
 If the patient desires prolongation of pregnancy past 
37 weeks, there must be evidence of normal fetal 
growth, amniotic fluid, umbilical artery Doppler 
studies, and twice weekly antenatal testing (at least 
one biophysical profile). 
 Prolongation past 38 weeks gestation is not 
recommended due to increased risk of stillbirth 
without anticipated neonatal benefit. 
o Monochorionic-Monoamniotic Twins  
 Elective delivery at 32-34 weeks after administration 
of antenatal corticosteroids, as risk from 
complications of prematurity are likely less than the 
risk of fetal demise for ongoing pregnancies.  
o Single-Twin IUFD  
 In monochorionic pregnancies, elective delivery at 
>34 weeks or at discovery if the IUFD occurs at a 
later gestational age. 
 In dichorionic pregnancies, elective delivery at 37 
weeks. 
 
G. Prior Classical Cesarean Delivery 
 
 Definitions:   
o Classical Cesarean Delivery:  A cesarean section with a 
vertical uterine incision that involves the upper muscular, 
contractile portion of the uterus. 
o TOLAC:  Trial of labor after cesarean section 
 
 Background 
o Greatest risk is uterine rupture in a subsequent 
pregnancy. Rupture risk is 4-9% if TOLAC attempted. 
o Uterine rupture may be associated with stillbirth, perinatal 
hypoxic brain injury, and maternal blood loss 
necessitating hysterectomy. 
o Rupture most often occurs as a complication during 
active labor, but can occur prior to labor. 
o Decision analyses balance RDS of newborn with preterm 
delivery against hypoxic ischemic encephalopathy and 
cerebral palsy after uterine rupture. 
 
 Timing of Delivery Guidelines (Level III) 
o Planned delivery via repeat cesarean section between 
36-37 weeks without amniocentesis. 
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H. Prior Myomectomy 
 
 Definition:  Myomectomy: Surgical removal of uterine myomas 
 
 Background 
o Myoma prevalence is approximately 25%. After 
myomectomy, 55% of women become pregnant. 
o Shift in care over time from laparotomy to laparoscopic 
approach. 
o There is lack of high-quality evidence to accurately 
assess rupture risk. 
o Type of closure (single or multilayer) and use of 
electrocautery  during myomectomy, as well as size and 
placement of fibroid,  may influence rupture risk. 
o No risk associated with myomectomy of a 
pedunculated myoma 
o Recommendation is for cesarean delivery if the 
myometrium was significantly compromised, i.e. the 
uterine cavity was entered or nearly entered during prior 
myomectomy, or if a large number of myomas were 
removed. 
o In cases where the myometrium was not significantly 
compromised, the patient can be managed similar to 
women with a prior low transverse cesarean section 
including continuous fetal monitoring in labor, early 
access to obstetric anesthesia, and labor in units 
equipped to perform an emergent cesarean delivery 
should it become necessary. 
 
 Timing of Delivery Guidelines (Level III) 
o Planned delivery via cesarean section at 37-38 weeks 
with FLM documented by amniocentesis or at 38 weeks 
without amniocentesis 
 
 
I.  Fetal Anomalies 
 
 Definition:  Ex Utero Intrapartum Treatment (EXIT): A procedure 
that maintains fetal oxygenation via the existing placental 
circulation at the time of cesarean delivery to allow for some 
procedure to be performed immediately on the fetus. 
 
 Background 
o 2-3% of pregnancies are complicated by a fetal anomaly. 
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o A small subset of pregnancies complicated by a fetal 
anomaly will require planning for location, mode, and 
timing of delivery. 
o For most anomalies, there is no benefit to delivering in 
the late preterm or early term period. 
o Specific anomalies carry ongoing risks to the fetus and/or 
mother.  Fetal risks include fetal death, hemorrhage, and 
ongoing or worsening organ damage. 
o Benefits of late preterm or early term delivery 
 Avoidance of ongoing risk to fetus in utero. 
 Allowing for delivery in a controlled setting with 
coordination of a multidisciplinary team. 
 Allow for direct care of the neonate with organ 
injury. 
o Risks of continued pregnancy near term 
 Risk of uterine rupture in women who have 
undergone invasive fetal intervention during 
pregnancy. 
 Preeclampsia/mirror syndrome if fetus has 
persistent hydrops. 
 Maternal hypertension in cases of fetal adrenal 
tumors. 
 Neonatal risk of unscheduled or unplanned 
delivery. 
 
 Timing of Delivery Guidelines (Level IIII) 
o Vast majority of anomalies do not require early delivery  
o Among the small subset of anomalies that may benefit 
from late preterm or early term delivery, there is a large 
amount of variability regarding optimal management. 
o Each management plan requires individualization, often 
in conjunction with Maternal Fetal Medicine, 
Neonatology, and Pediatric Surgery. 
o Elective delivery between 34-39 weeks can be 
considered for: 
 Suspected worsening of fetal organ damage 
 Potential for fetal intracranial hemorrhage (ex. vein 
of Galen Aneurysm, neonatal alloimmune 
thrombocytopenia) 
 When delivery prior to labor is preferred (ex. 
planned EXIT procedure) 
 Previous fetal intervention 
 Concurrent maternal disease (ex. preeclampsia, 
chronic hypertension) 
 Potential for adverse maternal effect from fetal 
condition 
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o Known lethal anomalies 
 Delivery after 39 weeks is recommended. 
 
J.  Oligohydramnios  
 
 Definition: Oligohydramnios: Maximum vertical pocket (MVP) <2 cm 
or an amniotic fluid volume of <5 cm. 
 
 Background 
o Oligohydramnios is associated with an increase in non-
reactive nonstress tests, fetal heart rate decelerations, fetal 
intolerance of labor, stillbirth, 5-minute Apgar scores <3, and 
meconium aspiration. 
o Optimal definition of oligohydramnios has not been 
determined; no evidence that one method is a better 
predictor of adverse neonatal outcome than the other. 
o Maximum vertical pocket has higher specificity in the 
preterm period and would lead to lower rates of delivery. 
 
 Timing of Delivery Guidelines (Level III) 
o Appropriate for gestational age 
 34-36 weeks- Maternal hydration followed by repeat 
fluid evaluation 2-12 hours later.  If no improvement, 
recommendation is for intensive fetal monitoring with 
delivery in the setting of non-reassuring fetal testing. 
 >37 weeks- elective delivery 
o Presence of comorbidities (chronic hypertension, 
documented placental disease, or IUGR) 
 >34 weeks- elective delivery 
 
 
K.  Diabetes 
 
 Definitions: Macrosomia- Birthweight greater than 4000 grams. 
 
 Background 
o Risks associated with diabetes related to disease type and 
presence/severity of end organ involvement. 
o Maternal risks (mostly with pre-gestational diabetes) 
 Worsening diabetic retinopathy 
 Nephropathy 
 Gastroparesis 
 Hypertensive disorders (including preeclampsia) 
 Cardiovascular disease (including congestive heart 
failure and ischemic coronary syndrome) 
 Ketoacidosis 
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o Fetal risks 
 Spontaneous abortion 
 Congenital anomalies (directly proportional to 
hemoglobin A1c in first trimester) 
 Intrauterine growth restriction 
 Macrosomia 
 Intrauterine fetal demise 
o Delivery risks 
 Shoulder dystocia 
 Brachial plexus injury 
o Neonatal risks 
 Hypoglycemia 
 Polycythemia 
 Hypocalcemia 
 Hyperbilirubinemia 
 Cardiac dysfunction secondary to septal hypertrophy 
 Respiratory distress syndrome 
o Timing of pulmonary maturation is related to degree of 
glucose control 
 
 Timing of Delivery Guidelines (Level I) 
o Pregestational diabetes 
 Well controlled- Delivery prior to 39 weeks is not 
recommended 
 Poorly controlled- 37-39 weeks after documented fetal 
lung maturity by amniocentesis 
o Gestational diabetes 
 Well controlled (by diet or medication)- Delivery prior 
to 39 weeks is not recommended 
 Poorly controlled- 37-39 weeks after documented fetal 
lung maturity by amniocentesis 
 
L.  Intrauterine Growth Restriction  
 
 Definitions: 
o Intrauterine Growth Restriction (IUGR):  An estimated fetal 
weight (EFW) less than the 10th percentile for gestational 
age. 
o Small for Gestational Age (SGA): Infants with birth weight 
less than the 10th percentile, representing small but normally 
grown infants (constitutionally small). 
 
 Background 
o Approximately 70% of infants with a birth weight less than 
the 10th percentile represent constitutionally small infants, 
and are not at risk for adverse perinatal outcomes.  
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o Approximately 30% have true IUGR and are at risk for 
complications including increased rates of perinatal mortality, 
meconium staining, emergency cesarean delivery, low Apgar 
scores, and low umbilical cord pH. 
o Findings associated with increased risk of fetal 
hypoxemia/academia in IUGR fetuses: 
 Biophysical profile score <4 
 Repetitive decelerations 
 Nonreactice nonstress test 
 Oligohydramnios 
 Absent or revere flow in the umbilical artery 
 Reversal of flow in the ductus arteriosus 
 
 Timing of Delivery Guidelines (Level III) 
o Singleton Gestation 
 Delivery regardless of gestational age 
 Persistent abnormal fetal surveillance 
suggesting imminent fetal jeopardy 
 Patients with severe preeclampsia or other 
maternal condition complicated by IUGR when 
maternal benefit from delivery outweighs fetal 
benefit of pregnancy continuation. 
 Delivery between 34-37 weeks 
 Biophysical profile score <4 
 Oligohydramnios 
 Repetitive fetal heart rate decelerations 
 Absent or reversed end diastolic flow in the 
umbilical artery 
 Delivery between 36-37 weeks 
 Elevated umbilical artery Dopplers 
 Delivery between 38-39 weeks 
 IUGR fetuses with normal Doppler studies and 
normal amniotic fluid volume (with twice weekly 
antenatal testing) 
o Twins 
 Delivery regardless of gestational age 
 Persistent abnormal fetal surveillance 
suggesting imminent fetal jeopardy 
 Patients with severe preeclampsia or other 
maternal condition complicated by IUGR when 
maternal benefit from delivery outweighs fetal 
benefit of pregnancy continuation. 
 Dichorionic twins with isolated IUGR- 36-37 weeks 
 Monochorionic-diamniotic twins with isolated IUGR- 
32-34 weeks 
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M.  Intrahepatic Cholestasis of Pregnancy  
 
 Definition: Intrahepatic Cholestasis of Pregnancy (ICP): Condition 
characterized by increased total serum bile acid concentrations and 
generalized pruritis. 
 
 Background: 
o Maternal outcomes are generally favorable  
o ICP is associated with increased risks of preterm labor, 
meconium staining, respiratory distress syndrome, and fetal 
death. 
o Fetal demise is seen in approximately 1-3% of patients with 
ICP, and rarely occurs prior to 36 weeks. 
o There are no antenatal tests that have been shown to predict 
the risk of fetal demise. 
 
 Timing of Delivery Guidelines (Level III) 
o Delivery at 37 weeks after fetal lung maturity documented by 
amniocentesis or at 38 weeks without amniocentesis  
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Appendix 1a: 
 
 
Summary of Clinical Practice Guideline: Indications for Late Preterm and Early-
Term Delivery 
 
Condition Timing of Delivery Guideline Alternative Timing of 
Delivery 
Previous Stillbirth >39 weeks 37-38 6/7 weeks with 
documented FLM 
Placenta Accreta 34-35 weeks  
Stable Placenta Previa (No 
Co-morbidities) 
36-37 weeks with documented FLM  
38 weeks without FLM 
 
Stable Placenta Previa 
(With Co-morbidities) 
36-37 weeks without FLM  
Vasa Previa (Cervical 
length >2.5cm) 
36 weeks  
Vasa Previa (Cervical 
length <2.5cm) 
34-35 weeks  
Severe gestational 
HTN/preeclampsia 
>34 weeks (for dx made >34 weeks)  
Mild gestational 
HTN/preeclampsia 
>37 weeks  
Dichorionic Twins 38 weeks 38-39 weeks with 
reassuring antenatal testing 
Monochorionic Diamniotic 
Twins 
36-37 weeks 37-38 weeks with 
reassuring antenatal testing 
Monoamniotic Twins 32-34 weeks  
Single-Twin IUFD 
     Monochorionic Twins 
     Dichorionic Twins 
 
>34 weeks 
37 weeks 
 
Prior Classical Cesarean 36-37 weeks   
Prior Myomectomy 37-38 weeks with documented FLM 
38 weeks without FLM 
 
Fetal Anomalies (See 
guideline for details) 
34-39 weeks  
Lethal fetal anomalies >39 weeks  
Oligohydramnios (AGA) 
      
    
 
 
 
>37 weeks 
 
(34-36 weeks- Maternal hydration with repeat 
AFI in 2-12 hrs; intensive monitoring if oligo 
persists) 
 
Oligohydramnios (IUGR or 
co-morbitities) 
>34 weeks  
Diabetes- Pregestational 
(Well-Controlled) 
>39 weeks  
Diabetes- Pregestational 
(Poorly-Controlled) 
37-39 weeks with documented FLM  
Diabetes- Gestational 
(Well-Controlled) 
>39 weeks  
Diabetes- Gestational 37-39 weeks with documented FLM  
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(Poorly-Controlled) 
Singleton IUGR 
 
Delivery regardless of GA 
-Persistent abnormal fetal surveillance 
-Severe preeclampsia or other maternal 
condition 
 
34-37 weeks 
-Biophysical profile score <4 
-Oligohydramnios 
-Repetitive fetal heart rate decelerations 
-Absent or reversed end diastolic flow in the 
umbilical artery 
 
36-37 weeks 
Elevated umbilical artery Dopplers 
 
38-39 weeks 
-IUGR with normal Dopplers and AFI 
 
Twins IUGR Delivery regardless of GA 
-Persistent abnormal fetal surveillance 
-Severe preeclampsia or other maternal 
condition 
 
36-37 weeks 
-Dichorionic twins with isolated IUGR 
 
32-34 weeks 
-Monochorionic twins with isolated IUGR 
 
Cholestasis of Pregnancy 37 weeks with documented FLM  
38 weeks without FLM 
 
Alloimmunization- Mild 
anemia 
37-38 weeks   
Alloimmunization- Severe 
anemia/Multiple fetal 
transfusions 
34-38 weeks, (Individualize each case)  
FLM-Fetal Lung Maturity 
IUGR- Intrauterine Growth Restriction 
IUFD- Intrauterine Fetal Demise 
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Appendix 2 
Full search terms 
 
 
 
("Labor, Induced"[Mesh] OR ((time factors[mesh] OR timing[tw]) AND 
(pregnan*[tw] OR labor[tw] OR delivery[tw])) OR (induced[tw] AND 
(delivery[tw] OR labor[tw]))) AND (stillbirth[tw] OR fetal demise[tw] 
OR fetal death[tw] OR Placenta Accreta[tw] OR placenta previa[tw] OR 
vasa previa[tw] OR pre-eclampsia[tw] OR preeclampsia[tw] OR 
multiple gestation[tw] OR prior classical Cesarean[tw] OR 
myomectomy[tw] OR fetal anomal*[tw] OR oligohydramnios[tw] OR 
cholestasis[tw] OR alloimmunization[tw] OR diabet*[tw]) AND 
retrospective[tw] 
 
 
 
The initial search was performed on March 5, 2013 and resulted in 786 
articles. The following standard filters culled the data to 513 articles: abstract 
and full-text available, humans and English. This cohort was further refined 
on title alone to include 55 articles. Exclusion criteria included case reports, 
editorials and letters, and research performed outside of Western Europe and 
North America. To be included, titles needed to indicate that the article 
addressed timing of delivery, outcomes, complications or delivery within the 
gestational age the CPG includes. Titles were also rejected if the article 
mainly addressed spontaneous preterm labor. Abstracts of articles further 
reduced the articles to a final number of 35. Of these 35 full articles for 
review, 20 gave recommendations for optimal time of delivery.  
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Appendix 3 
Evaluating the Evidence: Studies and Recommendations 
 
Studies were reviewed and evaluated for quality according to the method outlined by the 
U.S. Preventive Services Task Force. 
I Evidence obtained from at least one properly designed randomized controlled trial 
II-A Evidence obtained from well-designed controlled trials without randomization 
II-B Evidence obtained from well-designed cohort or case-control analytic studies, 
preferably from more than one center or research group 
II-C Evidence obtained from multiple time series with or without the intervention. 
Dramatic results in uncontrolled experiments also could be regarded as this type of 
evidence. 
III Opinions of respected authorities, based on clinical experience, descriptive studies, or 
reports of expert committees 
 
 
Recommendations were graded in the following categories: 
 
Level A: The recommendation is base on good and consistent scientific evidence. 
Level B: The recommendation is base on limited or inconsistent scientific evidence. 
Level C: The recommendation is based on expert opinion or consensus. 
 
 
Sources: 
http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm 
http://www.acog.org/Resources%20And%20Publications/Department%20Publications/Reading
%20the%20Medical%20Literature.aspx 
http://guideline.gov/index.aspx 
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Appendix 4, Part 1:  Articles that made no recommendation 
Identifiers Title Authored By 
Condition 
Addressed 
Give 
recommendation? 
Type of 
Article 
Notes - If no recommendation given, the reason 
why is included first  
PMID: 12593889 
Expectant 
management of 
severe 
preeclampsia 
and 
preeclampsia 
superimposed 
on chronic 
hypertension 
between 24 and 
34 weeks' 
gestation. 
Vigil-De Gracia 
P, Montufar-
Rueda C, Ruiz J. Preeclampsia No 
Retrospective 
cohort 129 
women 
Beyond the scope -Standard of care in this hospital was 
delivery at 34 wks for severe preeclampsia as an 
indication alone but the focus of the results was on poor 
outcomes if the pregnancy was expectantly managed to 
this point- my focus is beyond the scope of this study. 
PMID: 15458915 
ACOG Practice 
Bulletin #56: 
Multiple 
gestation: 
complicated 
twin, triplet, and 
high-order 
multifetal 
pregnancy. 
American 
College of 
Obstetricians 
and 
Gynecologists 
Committee on 
Practice 
Bulletins-
Obstetrics 
Multiple 
gestation No 
Guideline 
from 
American 
Congress of 
Obstetricians 
and 
Gynecologists 
Not enough evidence to make recommendation- Offers 
the information that 38 weeks for twins is the nadir of 
perinatal mortality, but stops short of a recommendation, 
citing not enough evidence for improved outcome with 
induction at this age. 
PMID: 22185537 
Perinatal 
outcome after 
ultrasound 
diagnosis of 
anhydramnios at 
term. 
Visvalingam G, 
Purandare N, 
Cooley S, 
Roopnarinesingh 
R, Geary M. Oligohydramnios No 
Review of the 
literature; 
expert opinion 
Beyond the scope- Focus of study was perinatal outcome 
after anhydramnios at term, neither condition applicable 
to my guideline 
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PMID: 12781410 
Pregnancy 
outcome after 
laparoscopic and 
laparoconverted 
myomectomy. 
Soriano D, 
Dessolle L, 
Poncelet C, 
Benifla JL, 
Madelenat P, 
Darai E. Myomectomy No 
Retrospective 
cohort 106 
women 
Beyond the scope- Focus of study was pregnancy 
outcomes, not timing of delivery. 
PMID: 22341806 
Pregnancy 
outcomes after 
transvaginal 
myomectomy by 
colpotomy. 
Rovio PH, 
Heinonen PK. Myomectomy No 
Prospective 
case control 
Observational study, without recommendations. Does not 
apply to my indications as these pregnancies were all 
delivered without complication at term 
PMID: 12389673 
Severe pre-
eclampsia 
remote from 
term: what to 
expect of 
expectant 
management. 
Blackwell SC, 
Redman ME, 
Tomlinson M, 
Berry SM, 
Sorokin Y, 
Cotton DB. PreEclampsia No 
Retrospective 
cohort study 
at a single 
hospital, 142 
women 
Beyond the scope- Outcome of study was latency period 
between diagnosis and delivery, not on optimal timing of 
delivery. Beyond the scope of the trial. 
PMID: 22071052 
Perinatal 
outcome in 
pregnancies 
complicated by 
isolated 
oligohydramnios 
diagnosed 
before 37 weeks 
of gestation. 
Melamed N, 
Pardo J, Milstein 
R, Chen R, Hod 
M, Yogev Y. Oligohydramnios No 
Retrospective 
cohort 108 
pregnancies 
Beyond the scope- Focus of study was perinatal outcome 
after diagnosis of low fluid, and study suggests (but does 
not recommend) that most of the problems with low 
amniotic fluid are actually due to iatrogenic preterm 
delivery, and not secondary to the low fluid itself. 
PMID: 18327870 
Risk factors 
associated with 
preterm birth 
according to 
gestational age 
at birth. 
Ofori BD, Le Tiec 
M, BÃ©rard A. Preterm birth No 
Three case-
control 
analyses 
Beyond the scope- this is an epidemiological case-control 
study looking at risk factors associated with preterm birth, 
and describes them while accounting for cofounding 
factors. 
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PMID: 22939722 
Impact of 
chorionicity on 
risk and timing 
of intrauterine 
fetal demise in 
twin 
pregnancies. 
McPherson JA, 
Odibo AO, 
Shanks AL, Roehl 
KA, Macones 
GA, Cahill AG. 
Multiple 
gestation and 
stillbirth No 
Retrospective 
cohort of 2161 
twin 
pregnancies 
Beyond the scope-This ia an observational and descriptive 
study, noting the frequency of the second twin's demise if 
one demise occurs- results show that monochorionic 
twins are at much higher risk of double fetal demise. They 
do not make recommendations about delivery beyond 
"these data can provide some guidance when counseling 
women" with twin pregnancies about outcomes. 
Recommendation data could be extrapolated. 
PMID: 17014813 
Maternal-fetal 
conditions 
necessitating a 
medical 
intervention 
resulting in 
preterm birth. 
Ananth CV, 
Vintzileos AM. Preterm birth No 
Population-
based 
retrospective 
cohort study 
Beyond the scope- This is a descriptive study, looking at 
reasons babies are born early, which include many of my 
indications. No recommendations were put forth  by the 
authors, and indeed the study was not attempting to 
answer my study question. 
PMID: 22035950 
Nonspontaneous 
late preterm 
birth: etiology 
and outcomes. 
Gyamfi-
Bannerman C, 
Fuchs KM, 
Young OM, 
Hoffman MK. Preterm birth No 
Retrospective 
cohort 2693 
women 
Institution-specific- the authors start with the premise 
that late-preterm and early term birth is associated with 
higher fetal morbidity, and they want to see whether such 
briths in their institution are evidence-based or non-
evidence based. The study ends up being a social 
commentary, suggesting that phyicians are more likely to 
deliver older, wealther women early if they want to be 
delivered early. However, they do question the validity of 
most of the indications our guideline covers, and it 
appears they would disagree with our findings- not 
because they mounted evidence against these indications, 
but because they don't believe the existing literature 
supports us. 
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PMID: 18715432 
The value of the 
short-term fetal 
heart rate 
variation for 
timing the 
delivery of 
growth-retarded 
fetuses. 
Serra V, 
Moulden M, 
Bellver J, 
Redman CW. 
Intrauterine 
growth 
restriction No 
Retrospective 
cohort 257 
fetuses 
No guts - "Timing the delivery of the most preterm and 
small fetuses remains a difficult task." And to be fair, their 
evidence could be used to support either side. 
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Appendix 4:  Part 2, Articles that made recommendations 
No. ID Title Authored By Condition Addressed 
Give 
recommendation? 
What is 
recommendation? 
Agree with 
CPG? 
Quality 
of 
Evidence 
Level of 
Evidence 
if 
guideline Type of Article 
Article 
Number Notes 
13 
PMID: 
10879335 
Optimal 
gestational age 
for twin delivery. 
Udom-Rice I, 
Inglis SR, 
Skupski D, 
Adams D, 
Chervenak 
FA. 
Multiple 
gestation Yes 
At or after 
38 wks Yes II-B 
 
Retrospective 
cohort of 329 
twin deliveries 13 
In uncomplicated 
twin gestations, 
delivery at 
between 36 and 
37 weeks' 
gestation was not 
associated with a 
reduction in 
neonatal 
complications 
compared with 
deliveries at or 
after 38 weeks' 
gestation. 
14 
PMID: 
22302586 
Prospective risk 
of late stillbirth in 
monochorionic 
twins: a regional 
cohort study. 
Southwest 
Thames 
Obstetric 
Research 
Collaborative 
(STORK). 
Multiple 
gestation Yes 
At or after 
36 wks No II-B 
 
Retrospective 
cohort of 3005 
twin 
pregnancies 14 
The data do not 
support a policy of 
elective delivery 
before 36 weeks' 
gestation in 
monochorionic 
twin pregnancies, 
which agrees with 
our finding that 
places optimal 
time to delivery at 
36-37 weeks. 
15 
PMID: 
21962631 
Previous stillbirth, 
late preterm, and 
early-term birth. Silver RM. Prior stillbirth Yes 
At or after 
39 wks Yes II-A 
 
Review of the 
literature, 
including 15 
The paper finds no 
good data to 
support earlier 
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retrospective 
trials 
delivery than after 
39 weeks, but 
does suggest that 
in cases of 
extreme maternal 
distress, earlier 
delievery with 
evidence of 
pulmonary 
maturity is 
acceptable. 
16 
PMID: 
21962629 
Management of 
late preterm and 
early-term 
pregnancies 
complicated by 
mild gestational 
hypertension/pre-
eclampsia. Sibai BM. 
Gestational 
hypertension Yes 
At or after 
37 wks Yes I 
 
Randomized 
controlled trial 
-secondary 
analyses of the 
HYPITAT trial 16 
This RCT finds 
good data to 
support induction 
at or after 37 wks 
for mild/stable 
preeclampsia, but 
finds no data to 
support either 
expectant 
management or 
earlier delivery in 
patient with 
complications. For 
our purposes, the 
data supports our 
recommendation. 
17 
Not in 
PubMed 
Placenta praevia, 
placenta praevia 
accreta and vasa 
praevia: diagnosis 
and management 
Royal College 
of Obstetricia 
and 
Gynecologists 
Previa and 
accreta Yes 
Previa- 
38wks; 
accreta- 36-
37wks 
Yes for 
accreta, 
yes for 
previa I 
Level 
A 
Guideline from 
Royal College 
of Obstetricia 
and 
Gynecologists 17 
Elective delivery 
by caesarean 
section in 
asymptomatic 
women is not 
recommended 
before 38 weeks 
of gestation for 
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placenta praevia, 
or before 36–37 
weeks of gestation 
for suspected 
placenta accreta. 
18 
PMID: 
16801956 
The impact of the 
interaction 
between 
increasing 
gestational age 
and obstetrical 
risk on birth 
outcomes: 
evidence of a 
varying optimal 
time of delivery. 
Nicholson 
JM, Kellar LC, 
Kellar GM. 
Hypertension 
and diabetes Yes 
HTN 39wks, 
DM 40-41 Yes II-B 
 
Retrospective 
cohort study 
at a single 
hospital 1995-
2003 18 
Their data 
supported our 
recommendation 
for Optimal Time 
to Delivery for 
these two 
conditions, and 
they searched the 
literature to 
corroborate their 
findings. 
19 
PMID: 
21962627 
Multiple 
gestations: timing 
of indicated late 
preterm and 
early-term births 
in uncomplicated 
dichorionic, 
monochorionic, 
and 
monoamniotic 
twins. 
Newman RB, 
Unal ER. 
Multiple 
gestation Yes At 38 wks Yes III 
 
Expert opinion 
and review of 
the literature 19 
Includes an 
expert-focused 
review of the 
literature and 
expert opinion, as 
well as a simple 
decision-tree, and 
agrees with our 
review of the 
literature. 
20 
PMID: 
22855972 
Multiple 
Pregnancy: The 
Management of 
Twin and Triplet 
Pregnancies in 
the Antenatal 
Period. 
National 
Collaborating 
Centre for 
Women's and 
Children's 
Health (UK). 
Multiple 
gestation Yes At 38 wks Yes I 
Level 
A 
Guideline from 
National 
Collaborating 
Centre for 
Women's and 
Children's 
Health 20 
This guideline 
reveiwed all the 
literature 
surrounding 
multiple 
gestations to an 
exhaustive degree. 
They had 195 
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references and 
fully covered all 
reasonable clinical 
questions. 
21 
PMID: 
22220321 
Hypertension in 
Pregnancy: The 
Management of 
Hypertensive 
Disorders During 
Pregnancy. 
National 
Collaborating 
Centre for 
Women's and 
Children's 
Health (UK). Hypertension Yes 
At or after 
38 wks Yes I 
Level 
A 
Clinical 
practice 
guideline from 
Royal College 
of 
Obstetricians 
and 
Gynaecologists 21 
This is another 
exhaustive 
guideline on 
management of 
hypertension in 
pregnancy. 
Includes a full 
systematic review 
of the literature 
and covers all 
management 
questions. 
22 
PMID: 
21962628 
The role of 
amniotic fluid 
assessment in 
indicated preterm 
delivery. Moore TR. Oligohydramnios Yes 
At or after 
34 wks Yes III 
 
Review of the 
literature; 
expert opinion 22 
The papers pulls 
together a review 
of the literature, 
and apparently 
used an expert-
focused approach 
similar to 
ours.Their results 
supported our 
conclusion. 
23 
PMID: 
21962624 
Optimal timing 
and mode of 
delivery after 
cesarean with 
previous classical 
incision or 
myomectomy: a 
review of the 
data. 
Landon MB, 
Lynch CD. 
Prior uterine 
incision Yes 
At or after 
39 wks Yes II-A 
Level 
B 
Practice 
guideline, 
Society of 
Obstetricians 
and 
Gynaecologists 
of Canada 23 
The paper 
acknowledges the 
paucity of 
randomized 
controlled trials, 
but "gleans" from 
the available 
research the best 
optimal timing. 
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They did a full 
review of the 
literature to come 
up with the 
guideline. 
24 
PMID: 
11228502 
Perinatal 
mortality and 
neonatal 
morbidity rates 
among twin pairs 
at different 
gestational ages: 
optimal delivery 
timing at 37 to 38 
weeks' gestation. 
Hartley RS, 
Emanuel I, 
Hitti J. 
Multiple 
gestation Yes 37-38 wks Yes II-A 
 
Population-
based 
retrospective 
10 year 
window 24 
The paper 
suggests that 
induction of labor 
should be 
routinely 
considered for 
twins at 37 to 38 
weeks' gestation. 
25 
PMID: 
21585638 
Perinatal 
mortality and 
mode of delivery 
in monochorionic 
diamniotic twin 
pregnancies â‰¥ 
32 weeks of 
gestation: a 
multicentre 
retrospective 
cohort study. 
Hack KE, 
Derks JB, 
Elias SG, van 
Mameren FA, 
Koopman-
Esseboom C, 
Mol BW, et 
al. 
Multiple 
gestation Yes 
NOT before 
32 weeks Yes II-B 
 
Multicenter 
retrospective 
cohort study 
of 465 women 25 
The paper 
specifically 
excludes twins 
with twin-to-twin 
transfusion 
syndrome, but 
given that caveat, 
makes a clear 
recommendation 
that agrees with 
our paper (which 
also does not 
address TTTT 
syndrome) 
26 
PMID: 
21962625 
Timing delivery of 
the growth-
restricted fetus. Galan HL. 
Intrauterine 
growth 
restriction Yes 
37-38 
singleton; 
34-36 TIUP Yes II-B 
 
Literature 
review and 
expert opinion 
consensus 26 
The research 
supports delivery 
by 37 to 38 weeks 
for singleton IUGR 
fetuses. In twin 
pregnancies with a 
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co-twin IUGR 
fetus, chorionicity 
also impacts 
timing of delivery, 
but delivery 
should occur by 
34-36 weeks. 
27 
PMID: 
16401210 
Monoamniotic 
twin pregnancy: a 
review of 
contemporary 
practice. Dickinson JE. 
Multiple 
gestation Yes 
Between 
32-34 wks Yes II-A 
 
Literature 
review 27 
Quote the 
multiple 
observational 
studies whose 
results contradict 
each other 
directly. 
Recommend, 
using ambilvant 
language, that it 
"appears prudent" 
to deliver at 32-34 
weeks. 
28 
PMID: 
21962626 
Indicated preterm 
birth for fetal 
anomalies. Craigo SD. Fetal anomalies Yes 
Case-
dependant Yes I 
 
Literature 
review, RCT 
review and 
expert opinion 
consensus 28 
Concluded the 
time to delivery 
will be anomaly-
specific, but do 
make specific 
recommendations 
for different 
anomalies based 
on their research.  
29 
PMID: 
21962630 
Timing of 
indicated late 
preterm and 
early-term birth 
in chronic medical 
complications: 
Catalano PM, 
Sacks DA. Diabetes Yes 
Case-
dependant Yes I 
 
Literature 
review, RCT 
review and 
expert opinion 
consensus 29 
Used as a main 
source for 
recommendations 
the ACOG Practice 
Bulletin, and 
agreed that their 
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diabetes. data supported 
the ACOG findings 
30 
PMID: 
21962623 
Indicated preterm 
birth for placenta 
accreta. Belfort MA. Accreta Yes 34-35 week Yes II-A 
Level 
B 
Literature 
review 30 
Given the paucity 
of good RCTs in 
this area, the 
paper pulled 
together all the 
known studies 
based on a 
systematic review 
of the literature to 
make the 
recommendations. 
Of all the papers, 
this one used the 
best methodology 
and graded the 
literature 
appropriately.  
31 
PMID: 
19300347 
ACOG Practice 
Bulletin No. 102: 
management of 
stillbirth. 
American 
College of 
Obstetricians 
and 
Gynecologists 
Committee 
on Practice 
Bulletins-
Obstetrics Prior stillbirth Yes 
At or after 
39wks Yes III 
Level 
C 
Guideline from 
American 
Congress of 
Obstetricians 
and 
Gynecologists 31 
They do not offer 
evidence to 
support this 
position, but they 
do offer a 
recommendation, 
which is 
considered the 
standard of 
practice in the 
field of OBGYN. 
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32 
PMID: 
15738045 
ACOG Practice 
Bulletin. Clinical 
Management 
Guidelines for 
Obstetrician-
Gynecologists. 
Number 60, 
March 2005. 
Pregestational 
diabetes mellitus. 
American 
College of 
Obstetricians 
and 
Gynecologists 
Committee 
on Practice 
Bulletins-
Obstetrics 
Pregestational 
diabetes Yes By due date Yes I 
Level 
A 
Guideline from 
American 
Congress of 
Obstetricians 
and 
Gynecologists 32 
Quoted 2 papers, 
one randomized 
controlled trial 
and one published 
algorithm based 
on retrospective 
review. Neither 
addressed timing 
of delivery as the 
focus of their 
research, but the 
practice bulletin 
draws inferences. 
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Appendix 4, Part 3:  Simplified presentation of articles that gave recommendation 
Identifiers Condition Addressed 
What is 
recommendation? 
Agree with 
CPG? 
Quality of 
Evidence 
Evidence 
Level Article Type 
21962629 Gest HTN ≥ 37 wks Yes I 
 
Analysis (sec) of RCT 
RCOG  Previa 38wks Yes  I Level A Guideline 
RCOG Acreta 36-37wks Yes I Level A Guideline 
22220321 HTN ≥ 38 wks Yes I Level A Guideline 
21962624 Prior ut incs ≥ 39 wks Yes II-A Level B Guideline 
19300347 Prior stillbirth ≥ 39 wks Yes III Level C Guideline 
15738045 Pregest DM By due date Yes I Level A Guideline 
22855972 Mult gest 38 wks Yes I Level A Guideline  
21962631 Prior stillbirth ≥ 39 wks Yes II-A 
 
Lit review/expert consensus 
21962627 Mult gest 38 wks Yes III 
 
Lit review/expert consensus 
21962628 Oligohydramnios ≥ 34 wks Yes III 
 
Lit review/expert consensus 
21962625 Growth restriction 37-38 singleton;  Yes II-B 
 
Lit review/expert consensus 
21962625 Growth restriction 34-36 TIUP 
   
Lit review/expert consensus 
21962626 Fetal anomalies Case-dependant Yes I 
 
Lit review/expert consensus 
21962623 Accreta 34-35 wks Yes II-A Level B Lit review/expert consensus 
16401210 Mult gestation 32-34 wks Yes II-A 
 
Literature review 
21962630 DM Case-dependant Yes I 
 
Literature review, RCT review and 
expert opinion consensus 
10879335 Mult gest ≥ 38 wks Yes II-B 
 
Retrospective cohort  
22302586 Mult gest ≥ 36 wks Yes  II-B 
 
Retrospective cohort  
16801956 HTN 39wks  Yes II-B 
 
Retrospective cohort  
16801956 DM 40-41 wks 
 
II-B 
 
Retrospective cohort  
21585638 Multiple gest 32 wks Yes II-B 
 
Retrospective cohort  
11228502 Mult gest 37-38 wks Yes II-A   Retrospective population 
 
